|
Uroplasty, Inc. - Comparative Business Analysis Snapshot
Business Description
Uroplasty, Inc.. The Group's principal activity is to develop, manufacture and market innovative, proprietary products for the treatment of voiding dysfunctions. The products include Urgent PC(R) system, which is office-based neurostimulation therapy for the treatment of urinary urgency, urinary frequency and urge incontinence symptoms often associated with overactive bladder (OAB) and Macroplastique(R), a urethral bulking agent for the treatment of adult female stress urinary incontinence due to intrinsic sphincter deficiency (ISD). The Urgent PC system uses percutaneous tibial nerve stimulation (PTNS) to deliver an electrical pulse that travels to the sacral nerve plexus, a control center for bladder function. It also offers Macroplastique(R), a minimally invasive, implantable soft tissue urethral bulking agent for the treatment of adult female stress urinary incontinence. The Group operates in the United States, Canada and Europe.
Competitor Analysis
This analysis compares Uroplasty, Inc. with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
